1. Emerging Basal Insulins for Diabetes

3. Program Goals

4. The Barrier of Hypoglycemia in Diabetes

5. Hypoglycemia and Cardiovascular Events

6. Insulin Glargine U-300

7. Reductions in Nocturnal Hypoglycemia With U-300

8. PK/PD Profile Glargine U-300

9. EDITION I-III (Meta-analysis) Nocturnal Hypoglycemia (Rates)

10. EDITION I-III (Meta-analysis) Body Weight

11. EDITION I-III (Meta-analysis) Basal Insulin Doses

12. Insulin Degludec An Ultra-Long-Acting Basal Insulin Analog

13. Insulin Degludec Pharmacodynamics at Steady State

14. Insulin Degludec Duration of Action

15. Insulin Degludec Low Within-Patient Variability

16. Insulin Degludec vs Insulin Glargine Hypoglycemia Results

17. Emerging Intensification Strategy

18. Peglispro (BIL)*

19. Key Takeaway Points of Next-Generation Basal Insulin Analogs

20. Abbreviations

21. Abbreviations (cont)

22. References

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)